Bola S. Hanna

Bola S. Hanna

Auto-generated profile, based on publicly available information

Bola S. Hanna

Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2018 in Leukemia
Verified
Journal Article
Closed access
PDF file
BHBola S. Hanna
Bola S. Hanna
PRPhilipp M. Roessner
Philipp M. Roessner
HYHaniyeh Yazdanparast
Haniyeh Yazdanparast
DCDolors Colomer
Dolors Colomer
ECElias Campo
Elias Campo
MSMartina Seiffert
Martina Seiffert

20 December 2018 in Leukemia
Verified
Journal Article
Closed access
PDF file
BHBola S. Hanna
Bola S. Hanna
PRPhilipp M. Roessner
Philipp M. Roessner
ASAnnika Scheffold
Annika Scheffold
BJBilly M. C. Jebaraj
Billy M. C. Jebaraj
YDYasmin Demerdash
Yasmin Demerdash
MSMartina Seiffert
Martina Seiffert

5 March 2020 in Haematologica
Verified
Journal Article
Open access
PDF file
BHBola S. Hanna
Bola S. Hanna
HYHaniyeh Yazdanparast
Haniyeh Yazdanparast
YDYasmin Demerdash
Yasmin Demerdash
PRPhilipp M. Roessner
Philipp M. Roessner
RSRalph Schulz
Ralph Schulz
MSMartina Seiffert
Martina Seiffert
Ibrutinib is a bruton’s tyrosine kinase (BTK) inhibitor approved for the treatment of multiple B-cell malignancies, including chronic lymphocytic leukemia (CLL). In addition to blocking B-cell receptor signaling and chemokine receptor-mediated pathways in CLL cells, that are known drivers of disease, ibrutinib also affects the microenvironment in CLL via targeting BTK in myeloid cells and IL-2–inducible T-cell kinase (ITK) in T-cells. These non-BTK effects were suggested to contribute to the success of ibrutinib in CLL. By using the Eµ-TCL1 adoptive transfer mouse model of CLL, we observed that ibrutinib effectively controls leukemia development, but also results in significantly lower numbers of CD8+ effector T-cells, with lower expression of activation markers, as well as impaired proliferation and effector function. Using CD8+ T-cells from a T-cell receptor (TCR) reporter mouse, we verified that this is due to a direct effect of ibrutinib on TCR activity, and demonstrate that co-stimulation via CD28 overcomes these effects. Most interestingly, combination of ibrutinib with blocking antibodies targeting PD-1/PD-L1 axis in vivo improved CD8+ T-cell effector function and control of CLL. In sum, these data emphasize the strong immunomodulatory effects of ibrutinib and the therapeutic potential of its combination with immune checkpoint blockade in CLL.